Skip to main content
logo
Bayer Aktiengesellschaft (BAYRY)
OTCMKTS · Delayed Price · Currency is USD
11.78
-0.01 (-0.08%)
Apr 10, 2026, 10:43 AM EST

Revenue

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Crop Science Revenue
21.62B22.26B
Crop Science Revenue Growth
-2.86%-4.35%
Pharmaceuticals Revenue
17.83B18.13B
Pharmaceuticals Revenue Growth
-1.67%0.28%
Consumer Health Revenue
5.80B5.87B
Consumer Health Revenue Growth
-1.16%-2.60%
All Other Segment Revenue
302.00M327.00M
All Other Segment Revenue Growth
-7.65%37.40%
Enabling Functions and Consolidation Revenue
20.00M19.00M
Enabling Functions and Consolidation Revenue Growth
5.26%-9.52%
Revenue (Other)
--
Revenue (Total)
45.58B46.61B
Revenue (Total) Growth
-2.21%-2.16%

Revenue by Geography

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Europe/Middle East/Africa Revenue
13.50B13.98B
Europe/Middle East/Africa Revenue Growth
-3.43%-0.75%
North America Revenue
16.73B16.48B
North America Revenue Growth
1.50%1.37%
Asia/Pacific Revenue
7.52B8.07B
Asia/Pacific Revenue Growth
-6.85%-3.56%
Latin America Revenue
7.83B8.08B
Latin America Revenue Growth
-3.06%-9.52%
Revenue (Total)
45.58B46.61B
Revenue (Total) Growth
-2.21%-2.16%

Adjusted EBITDA

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Crop Science Adjusted EBITDA
4.19B4.33B
Crop Science Adjusted EBITDA Growth
-3.17%-14.15%
Pharmaceuticals Adjusted EBITDA
4.53B4.72B
Pharmaceuticals Adjusted EBITDA Growth
-4.17%-9.00%
Consumer Health Adjusted EBITDA
1.34B1.37B
Consumer Health Adjusted EBITDA Growth
-1.83%-3.19%
All Other Segment Adjusted EBITDA
277.00M62.00M
All Other Segment Adjusted EBITDA Growth
346.77%-61.96%
Enabling Functions and Consolidation Adjusted EBITDA
-662.00M-352.00M
Operating Income (Total)
-1.08B-71.00M
Updated Dec 31, 2025. Data Source: Fiscal.ai.